|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
platinum-based antineoplastic agent
|
|
gptkbp:administered_in_combination_with
|
gptkb:leucovorin
gptkb:5-fluorouracil
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XA03
|
|
gptkbp:CASNumber
|
61825-94-3
|
|
gptkbp:chemicalFormula
|
C8H14N2O4Pt
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
hypersensitivity to platinum compounds
|
|
gptkbp:discoveredBy
|
gptkb:Yves_Kidani
|
|
gptkbp:drugClass
|
alkylating agents
|
|
gptkbp:eliminationHalfLife
|
9-25 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstDescribed
|
1976
|
|
gptkbp:form
|
powder for solution
|
|
gptkbp:has_platinum_atom
|
true
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oxaliplatin
|
|
gptkbp:KEGGID
|
D01857
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Eloxatin
|
|
gptkbp:mechanismOfAction
|
DNA crosslinking
|
|
gptkbp:MeSH_ID
|
D000077162
|
|
gptkbp:metabolism
|
non-enzymatic biotransformation
|
|
gptkbp:molecularWeight
|
397.29 g/mol
|
|
gptkbp:originatedIn
|
gptkb:France
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL19045
DB00526
6857598
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
peripheral neuropathy
allergic reactions
myelosuppression
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:synonym
|
trans-L-diaminocyclohexane oxalatoplatinum(II)
|
|
gptkbp:toxicity
|
hepatotoxicity
nephrotoxicity
neurotoxicity
ototoxicity
|
|
gptkbp:UNII
|
04ZR38536J
|
|
gptkbp:used_in_regimen
|
FOLFOX
XELOX
|
|
gptkbp:usedFor
|
colorectal cancer
|
|
gptkbp:bfsParent
|
gptkb:Cisplatina
|
|
gptkbp:bfsLayer
|
7
|